Germline mutations in the fumarate hydratase gene (FH) These results provide further evidence for the role of the FH gene in the pathogenesis of MCL.
Multiple cutaneous and uterine leiomyoma syndrome (MCL; MIM #150800), in which affected individuals develop associated skin and uterine leiomyomas, is a disorder inherited in an autosomal dominant pattern. The skin lesions usually appear between the early teens and the fourth decade of life. For the majority of affected women, uterine fibroids of early onset usually require hysterectomy or myomectomy (Stewart, 2001) . In some families with MCL, the disease is associated with an additional predisposition to type II papillary renal cell carcinoma ).
The genetic locus for MCL was recently mapped to chromosome 1q42. 3 (Tomlinson et al, 2002) . The gene product for FH is fumarate hydratase, part of the tricarboxylic acid cycle involved in energy production for the cell. Dominant mutations in FH cause MCL in approximately 59.5% of affected individuals (Tomlinson et al, 2002) . Based on its role in MCL, FH has been hypothesized to act as a tumor suppressor gene in sporadic tumors as well. However, two recent reports show a very low frequency of FHmutations in different types of tumors, including uterine and cutaneous leiomyomas, leiomyosarcoma, and renal cell carcinoma (Barker et al, 2002; Kiuru et al, 2002) . Whether FH plays a role in sporadic tumorigenesis remains to be determined. Mutations in three different subunits of succinate dehydrogenase, another enzyme of the tricarboxylic acid cycle, also correlate with a high incidence of tumors, in particular, hereditary paragangliomas (Baysal et al, 2001 ). Interestingly, autosomal recessive mutations in the FH gene have been implicated in fumarate hydratase deficiency, which presents with progressive encephalopathy and developmental delay (MIM #606812). Accordingly, Tomlinson et al (2002) reported a patient with fumarase deficiency whose mother, a carrier for an FH mutation, developed skin leiomyoma. How these two phenotypically distinct disorders are linked to different types and combinations of mutations in FH calls for further investigation.
In this study, we report the clinical and mutational analysis of five families with MCL. We have identified five new mutations in the FH gene, further supporting the role of FH in MCL.
Materials and methods

Human subjects
We have identified five families with dominantly inherited MCL, comprising 16 affected individuals available for this study. 
Mutation analysis
Genomic DNA was isolated from peripheral blood collected in EDTA-containing tubes using the PureGene DNA isolation kit (Gentra Systems, Minneapolis, MN). To screen for mutations in the human FH gene, all exons and splice junctions were PCR-amplified from genomic DNA. PCR primers are shown in Table I . PCR products were sequenced in an ABI Prism 310 automated sequencer, using the ABI Prism BigDye terminator cycle sequencing ready reaction kit (PE Applied Biosystems, Foster City, CA), following purification in Centriflex gel filtration cartridges (Edge Biosystems, Gaitherburg, MD). Mutations were identified by visual inspection and comparison with control sequences generated from unrelated unaffected individuals.
To confirm the mutations identified, direct and mismatched PCR were used. The nonsense mutation Q142X and the missense H275Y and V351L were confirmed by digestion of the corresponding PCR products with BstNI, BspHI, and MaeIII, respectively. In the case of S115I, a reverse mismatched primer (5'-CCT AAC ATT TCA ATT GCT CTA TAG-3') was used to introduce an Alu I restriction site. Finally, the PCR product corresponding to frameshift mutation 1081del4 was run on a polyacrylamide gel and visualized by ethidium bromide staining.
All five DNA variants were tested in a mixed control population of 46-49 individuals. The missense variants S115I, H275Y, and V351L were tested in an additional sample of 32-43 control individuals.
Results
Clinical findings
The patients in the five families with MCL ( Figure 1 Of the 9 women with uterine leiomyoma, 7 had coexisting skin leiomyoma and 2 had uterine leiomyoma alone. Six of these patients with affected uteri eventually underwent hysterectomy or myomectomy.
Mutation analysis in the FH gene
We have analyzed five families with dominantly inherited MCL for FH mutations. All were found to carry heterozygous mutations in the FH gene (Table II) . None of these mutations have been previously reported in patients with MCL or fumarate hydratase deficiency, and each of them was unique to a single family. The fact that they have not been detected in the control population excludes them as common polymorphisms.
A C>T transition at nucleotide position 553, which results in the nonsense mutation Q142X (amino acid residue 185 in the mitochondrial isoform), was identified in family MCL-2, and a deletion of four nucleotides in exon 7 was found in family MCL-5. This frameshift mutant allele is the result of Table II ).
Discussion
In this study, we have identified five new FH"mutations" in MCL families, further supporting the role of this housekeeping gene in tumorigenesis. The nature of these mutations, including nonsense, frameshift, and missense mutations, clearly supports the role of the FH gene in MCL.
Nonetheless, the involvement of a housekeeping gene such as FH in tumorigenesis unveils new questions about the etiologic mechanism underlying MCL.
Our study has identified a heterozygous nonsense (Q142X) and a frameshift mutation (1081del4) in two of the families. The most likely fate of the mRNA of these mutant alleles would be nonsensemediated mRNA decay, where the nonsense-bearing mRNA is recognized and degraded soon after transcription (Frischmeyer and Dietz, 1999) . Unfortunately, mRNA samples from these families were not available for further testing and therefore other possible mechanisms such as translation into a truncated protein or exon skipping cannot be ruled out.
Regarding the three missense changes identified in our study, S115I (MCL-4), H275Y (MCL-1), and V351L (MCL-3), the possibility of these being rare polymorphisms cannot be completely excluded, because a mixed control population was used owing to unavailability of a sufficient number of ethnically matched controls. This is especially true for V531L, where both amino acids consist of hydrophobic side chains with only one carbon difference. It is noteworthy, however, that 7 of the 17 mutations reported by Tomlinson et al (2002 ) were also missense mutations. The affected amino acid residues S115, H275, and V351 are conserved among human, pig, rat, and mouse FH.
Cosegregation between the mutations and the MCL phenotype was confirmed for families MCL-1 (H275Y) and MCL-3 (V351L), for which blood samples from several affected family members were available. These two missense variants show reduced penetrance for the skin and uterine lesions. H275Y was identified in family MCL-1 (Figure 1 In family MCL-3 (Figure 1 ), on the other hand, the V351L missense substitution was present in three women, one of them with both uterine and skin involvement and the remaining two with only uterine myoma. The grandmother in this family, reported to have uterine polyps on a biopsy report, did not carry the mutation. For family MCL-2 (Q142X; Figure 1 ) the mutation was only present in the affected individual and his mother and absent in the unaffected father and sibling. Since no family history of MCL was reported for the affected member of this family, the carrier mother will be reexamined for skin and uterine lesions. The missense variant S115I in family MCL-4 was present in the affected family member only and absent in the remaining three unaffected siblings ( Figure 1 ). The parents of these individuals were not available for the study. Finally, only one individual from family MCL-5 ( Figure 1, Figure 2 ), an affected woman, was available for examination and was heterozygous for the frameshift mutation. None of the families studied here suffered from any other type of tumor, including papillary renal cell cancer.
In summary, of 11 female patients, 7 exhibited concurrent skin and uterine leiomyoma involvement.
Of the remaining 4 affected female patients, 2 had skin lesions only and 2 had uterine leiomyoma alone. Patients from the same family may display different phenotypic expression of the disease.
For example, in family MCL-3, a mother with uterine leiomyoma and no skin lesions had two daughters, one with both skin and uterine lesions and the other with uterine involvement only. One of the implications of gene identification for inherited susceptibility to tumorigenesis is the possible role they may play in the more common sporadic presentation of the same type of tumors.
Families with MCL present with benign skin and uterine leiomyomas, the latter being a major public health issue. In addition, the aggressive papillary renal cell carcinoma can also be associated with MCL, as well as leiomyosarcoma ). 
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